<DOC>
	<DOCNO>NCT00534625</DOCNO>
	<brief_summary>A single intravenous injection zileuton ( 150 300 mg ) administer patient stable asthma . The goal determine zileuton i.v . produce rapid increase FEV1/PEFR effect see . The safety route administration zileuton also study . PK obtain population base method .</brief_summary>
	<brief_title>Assessment PFT , Safety , PK Zileuton Injection Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Zileuton</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>1 . Male female patient 12 year age old 2 . Diagnosis asthma current ATS guideline 3 . FEV1 480 % . 4 . Reversibility least 13 % bronchodilator treatment 5 . Must willing hold SABA 6 hour ICS 24 hour prior treatment . 6 . Informed consent 1 . Females child bear potential unless use birth control 2 . Uncontrolled systemic disease 3 . Known hypersensitivity zileuton component zileuton injection . 4 . Upper low respiratory tract infection within last 2 week 5 . Admission hospital ER visit asthma exacerbation within last 3 month 6 . Course oral parenteral steroid within last 3 month 7 . Current smoker H/O &gt; 15 pack year 8 . Creatinine &gt; 1.5 x ULN 9 . ALT &gt; 3 x ULN 10 . BP &lt; 100 ( systolic ) 11 . H/O HIV 12 . H/O alcohol drug abuse 13 . Patients take Xolair , theophylline , montelukast , zafirlukast , nedocromil , cromolyn sodium , Zyflo ( within past 7 day ) , warfarin , propranolol , inhaled anticholinergic , LABA . 14 . Pregnant breast feeding females 15 . Current participation participation experimental drug study within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Asthma , exacerbation , pulmonary function</keyword>
</DOC>